The Company


New Haven Pharmaceuticals, Inc.
is privately held.

New Haven Pharmaceuticals (NHP) is a specialty pharmaceuticals company developing proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications that represent significant market opportunities. The company's novel product pipeline employs proprietary, oral, controlled-release technologies, as well as intellectual property licensed from Yale University, which will
enable optimal dosing, safety, efficacy and patient convenience.

A US NDA for the Company's lead product, DURLAZA™, is expected to be submitted to the FDA in Q3 2014, with approval and US launch expected in Q3 2015.

Micropump© Aspirin Products

  • DURLAZA™ - a novel aspirin product. DURLAZA™ is designed to be slowly released into the bloodstream over 24 hours, in contrast to the other available aspirin products, which are released over a shorter period of time into the bloodstream. This product is specifically designed and will be indicated for those patients at higher risk for a secondary stroke or acute cardiac event.
  • NHP-554CZ - a second generation combination Micropump© Aspirin product (successor to NHP-554C), incorporating proprietary Yale University technology utilizing zinc salts. NHP plans a clinical program which is intended to show an improved GI safety profile of NHP 554CZ as compared with other aspirin products.